Publication Synopsis Thyroid cancer is the most prevalent endocrine malignancy. The radioactive iodine used in the treatment of thyroid cancer has found to be associated with the increased risk of second primary malignancy in the young survivals the disease. A study published in the Journal of National Cancer Institute has investigated the association of radioactive iodine and its dose with the subsequent malignancies in the thyroid cancer patients with a positive outcome.
Thyroid cancer is the most prevalent endocrine malignancy with reported increasing rate of 6.6 % per year. With appropriate treatment, patients with thyroid cancer have shown favorable prognosis with 10-year survival rate which is estimated to be greater than 90%. However, several epidemiological studies have reported that the young survivals of most thyroid cancer patients have shown increased risk of subsequent…
